Total studies: Included, Excluded. Total eligible, total arms

From Analysis:

1. General
   1. No. of studies by region and %
   2. No. of studies by follow-up duration, % (6 & 12)
   3. No. of studies by Relapse diagnosis method
   4. Total drug regimen and major ones
2. Overall estimates from MA:, RE estimates (change some method), Tau2 estimate, Prediction interval, Bias adjusted estimates

Table: No of arms, T/I/R

* 1. Total treated, initially cured and relapses at 6m.
  2. Table 1:
     1. Relapse prop by region, drug, infection type, diagnosis, time
     2. 6 vs 12 month vs 6-12 month

1. Estimates for India
   1. Table 2:
      1. Overall and by subgroups
      2. Dose response SD LamB
      3. Time trend for PA
   2. Dose response: Odds ratio for dosage, adjust for VL infection and diagnosis method. Does not make sense to adjust for publication year.
   3. The odds ratio (OR) of relapse for PA regimens in ISC compared to L-AmB was and adjusted OR with diagnostic method and the type of VL infection. Also time period further
2. Estimates from EA
3. Estimates from all other regions
4. Relapses after 6 month
   1. Studies with fu>6m and those reported at 12m
   2. Total patients initially cured, relapses. Relapses by 6 and 12 month
   3. Studies by region
   4. Estimates at 6 month and 12 month. And also 6-12 month.
   5. 6 month follow-up to miss how many?
5. Subgroup analysis
   1. Proportions of studies in each category (% and numbers)
   2. Estimate for 1-2 categories
6. Sensitivity
   1. Bias adjusted overall estimate